Rep. James Comer (R-Kentucky), the lead Republican on the House Oversight Committee, has sent a letter to Food & Drug Administration (FDA) Acting Commissioner Janet Woodcock expressing concerns over more reports that the Biden Administration is improperly interfering at the […]
(READ) Rep. Comer asks FDA about ‘improper interference’ in Covid booster approval Read More »
As reported in these podcasts, attorney Aaron Siri has been trying to force the federal government to turn over public health documents that we own at a more reasonable rate than the agency proposed. Now, a court has sided with
(READ) FDA forced to produce public documents at more reasonable rate Read More »
Last summer, Florida became was one of the heaviest promoters of monoclonal antibody treatments (MAB) for its residents infected with Covid-19. By September, Florida was buying treatments directly from pharmaceutical manufacturers. But since then, the federal government’s Human and Health
Attorney Aaron Siri is in a pitched court battle over important vaccine safety documents the government is keeping hidden from the American public.Â
Fighting the Govt. for Pfizer-BioNTech Covid-19 Vaccine Safety Documents (PODCAST) Read More »
The following is from Medpage. The first long-acting injectable for HIV prevention has now been approved for use, the FDA announced on Monday. Long-acting injectable cabotegravir (CAB-LA, branded as Apretude) is administered as a monthly injection for the first 2 months,
(READ) FDA approves 1st monthly shot to prevent HIV Read More »
The following is from the Substack of attorney Aaron Siri, who is representing groups challenging vaccine mandates in court. FDA Rep a No-Show at Court Hearing, Citing COVID Concerns; FDA Releases Additional Docs; and FDA Triples Down On 75-Year Production
(READ) Govt. continues to stall in releasing public documents on vaccine safety Read More »
Below is an excerpt from Medpage Today. With the release of updated data, oral antiviral molnupiravir to treat high-risk COVID-19 showed only a 30% reduction in the risk of hospitalization and death, according to briefing documents from FDA staff. The
(READ) Review shows Merck’s newly-approved pill for Covid-19, only 30% effective Read More »
The following is an excerpt from Medpage Today. A man treated with the recently approved Alzheimer’s drug aducanumab (Aduhelm) had six amyloid-related imaging abnormality (ARIA) episodes, researchers reported. Over 44 months in a long-term extension study, the Alzheimer’s disease patient
